DCGI gives nod to Cipla to sell Covid19 drug


Content Team
Image Credit: Shortpedia

The Drug Controller General of India has given its nod to pharmaceutical giant Cipla to sell anti-viral drug favipiravir to treat COVID-19. Cipla will launch favipiravir as "Ciplenza" in the first week of August and will sell it for Rs 68 per 200 mg tablet. Other Indian pharma firms like Glenmark Pharmaceuticals are working towards the generation of generic versions of favipiravir that has originally been developed by Japan.